Significant pharmaceutical investment in Hungary – Egis develops in Körmend with state support

The investment is an integral part of the ongoing development program, within the framework of which the pharmaceutical giant is modernizing the tablet plant operating at the Körmend site, the infrastructure required for the production of galenic preparations – i.e. non-solid pharmaceutical forms, such as creams, ointments, gels, suppositories, solutions – and the packaging plant, and is also expanding their capacity. All this further strengthens the strategic role of the Körmend plant in the company’s operations and contributes to Egis being able to respond even faster and more flexibly to constantly changing market demands.

“This development not only increases our production capacities, but also represents a technological renewal, which allows us to operate even more efficiently and sustainably. This is a pledge of competitiveness, which, together with the innovative approach, has traditionally characterized Egis. This investment also indicates that we intend our Körmend site, which is the largest employer in the city, to continue to be of strategic importance in the future,”

– said Csaba Poroszlai, CEO of Egis Gyógyszergyár Zrt., also emphasizing that the goal is for the company to use the best available technologies and tools. “These not only comply with the strictest international standards, but also significantly increase efficiency, thus increasing the company’s competitiveness and ultimately the performance of the domestic economy.”

Egis has continuously and intensively developed its Körmend site in recent years, where almost 29 billion forints of job-creating investments have been implemented with state support since 2018. Together with the developments announced now, all this will determine and secure the future of pharmaceutical manufacturing in the region in the long term.